0001213900-24-042966.txt : 20240514 0001213900-24-042966.hdr.sgml : 20240514 20240514162619 ACCESSION NUMBER: 0001213900-24-042966 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240514 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Citius Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001506251 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273425913 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38174 FILM NUMBER: 24944803 BUSINESS ADDRESS: STREET 1: 11 COMMERCE DRIVE STREET 2: 1ST FLOOR CITY: CRANFORD STATE: NJ ZIP: 07016 BUSINESS PHONE: (908) 967-6676 MAIL ADDRESS: STREET 1: 11 COMMERCE DRIVE STREET 2: 1ST FLOOR CITY: CRANFORD STATE: NJ ZIP: 07016 FORMER COMPANY: FORMER CONFORMED NAME: Trail One, Inc. DATE OF NAME CHANGE: 20110314 FORMER COMPANY: FORMER CONFORMED NAME: TrailOne, Inc. DATE OF NAME CHANGE: 20101119 8-K 1 ea0206086-8k_citius.htm CURRENT REPORT
false 0001506251 0001506251 2024-05-14 2024-05-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) May 14, 2024 

 

 

 

Citius Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Nevada

(State or other jurisdiction of incorporation)

 

001-38174   27-3425913
(Commission File Number)   (IRS Employer Identification No.)

 

11 Commerce Drive, 1st Floor, Cranford, NJ   07016
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (908) 967-6677

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Title of each class

  

 

Trading Symbol(s)

  

Name of each exchange on which registered

Common stock, $0.001 par value   CTXR   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On May 14, 2024, we issued a press release announcing our results of operations for the second quarter of fiscal 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

 

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press release, dated May 14, 2024.
     
104   Cover Page Interactive Date File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CITIUS PHARMACEUTICALS, INC.
   
Date: May 14, 2024 /s/ Leonard Mazur
  Leonard Mazur
  Chairman and Chief Executive Officer

 

 

2

 

 

 EX-99.1 2 ea020608601ex99-1_citius.htm PRESS RELEASE, DATED MAY 14, 2024

Exhibit 99.1 

 

 

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update

 

Mino-Lok data analysis on track with topline results anticipated this quarter

 

LYMPHIR biologics license application accepted with PDUFA target action date set for August 13, 2024

 

CRANFORD, N.J., May 14, 2024 -- Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal second quarter 2024 ended March 31, 2024.

 

Second Quarter 2024 Business Highlights and Subsequent Developments

 

-LYMPHIR™ (denileukin diftitox) biologics license application (BLA) accepted by the U.S. Food and Drug Administration (FDA) with August 13, 2024, assigned as Prescription Drug User Fee Act (PDUFA) target action date;

 

-Data analysis underway for completed Mino-Lok® Pivotal Phase 3 trial with topline results anticipated in calendar 2Q 2024;

 

-Continued engagement with FDA following end of Phase 2b meeting to determine next phase in the development of Halo-Lido for the treatment of hemorrhoids;

 

-Merger of our wholly owned subsidiary with TenX Keane Acquisition (Nasdaq: TENK) to form publicly listed Citius Oncology, Inc. is progressing and pending review by Securities and Exchange Commission (SEC) and TENK shareholder approval;

 

-Robert Smith elected to the Citius Board of Directors at the Annual Meeting of Stockholders; and,

 

-Completed $15 million registered direct offering in April 2024 extending the Company’s cash runway.

 

Financial Highlights

 

-Cash and cash equivalents of $12.6 million as of March 31, 2024;

 

-$15 million in gross proceeds from a registered direct offering on April 30, 2024, extends the Company’s cash runway through December 2024;

 

-R&D expenses were $3.6 million and $6.2 million for the three and six months ended March 31, 2024, respectively, compared to $4.7 million and $8.2 million for the three and six months ended March 31, 2023, respectively;

 

-G&A expenses were $4.3 million and $7.9 million for the three and six months ended March 31, 2024, respectively, compared to $4.8 million and $7.4 million for the three and six months ended March 31, 2023, respectively;

 

 

 

-Stock-based compensation expense was $3.1 million and $6.1 million for the three and six months ended March 31, 2024, respectively, compared to $1.2 million and $2.4 million for the three and six months ended March 31, 2023, respectively; and,

 

-Net loss was $8.5 million and $17.8 million, or ($0.05) and ($0.11) per share for the three and six months ended March 31, 2024, respectively, compared to a net loss of $10.5 million and $14.1 million, or ($0.07) and ($0.10) per share for the three and six months ended March 31, 2023, respectively.

 

“I am pleased to share that we made solid progress this quarter as we focused on execution and managing our finances. The data analysis of our late-stage asset, Mino-Lok, the only treatment of its kind in development to salvage infected catheters, remains on track. We look forward to reporting the topline results later this quarter. Once we review the results, we plan to engage with the FDA to determine the optimal next steps in the program and look forward to advancing this much-needed alternative to the current standard of care, which often involves painful and costly catheter removal and replacement,” stated Leonard Mazur, Chairman and CEO of Citius.

 

“Importantly, the BLA submission for LYMPHIR, our novel IL-2 receptor targeted oncology therapy, was accepted by the FDA, and assigned a late summer 2024 PDUFA target action date. In anticipation of potential approval, we continue to align the organization for a successful launch,” added Mazur.

 

“Despite a tough capital market environment for pre-revenue companies, we successfully completed a $15 million registered direct offering, expanding our cash runway and providing capital to support the execution of our strategic plan. We believe that the merger of our oncology subsidiary with TenX to form a publicly listed company will make our company more attractive to investors and increase the value of our assets. This transaction is progressing, and we expect it to be completed in the coming months as we finalize SEC review and await approval by TENK shareholders. As we continue to meet our goals, we believe additional opportunities to strengthen our capital structure will become available,” concluded Mazur.

 

second QUARTER 2024 Financial Results:

 

Liquidity

 

As of March 31, 2024, the Company had $12.6 million in cash and cash equivalents.

 

As of March 31, 2024, the Company had 159,094,781 common shares outstanding.

 

Based on our cash and cash equivalents as of March 31, 2024, and after giving effect to a capital raising that closed on April 30, 2024, we expect to have sufficient funds to continue our operations through December 2024. We expect to raise additional capital in the future to support our operations beyond December 2024.

 

Research and Development (R&D) Expenses

 

R&D expenses were $3.6 million for the quarter ended March 31, 2024, compared to $4.7 million for the quarter ended March 31, 2023. For the six months ended March 31, 2024, R&D expenses were $6.2 million as compared to $8.2 million during the six months ended March 31, 2023, a decrease of $1.9 million. The decrease primarily reflects incremental costs related to the completion of the Mino-Lok Phase 3 trial and remediation activities for the LYMPHIR BLA resubmission, offset by lower costs in the current period due to the completion of the Halo-Lido Phase 2b trial.

 

2

 

 

We expect that research and development expenses will stabilize at current levels in fiscal 2024 as we focus on the commercialization of LYMPHIR, complete our Phase 3 trial for Mino-Lok, and analyze the data from our Phase 2b trial and begin planning our Phase 3 trial for Halo-Lido

 

General and Administrative (G&A) Expenses

 

G&A expenses were $4.3 million for the quarter ended March 31, 2024, compared to $4.8 million for the quarter ended March 31, 2023. The decrease was primarily due to lower costs for pre-launch and market research activities associated with LYMPHIR during the period.

 

For the six months ended March 31, 2024, G&A expenses were $7.9 million as compared to $7.4 million during the six months ended March 31, 2023. The primary reason for the increase was higher costs for pre-launch and market research activities associated with LYMPHIR.

 

General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting, and corporate development services, and investor relations expenses.

 

Stock-based Compensation Expense

 

For the quarter ended March 31, 2024, stock-based compensation expense was $3.1 million as compared to $1.2 million for the quarter ended March 31, 2023. For the six months ended March 31, 2024, stock-based compensation expense was $6.1 million as compared to $2.4 million for the six months ended March 31, 2023. The increase is primarily due to the Citius Oncology stock plan.

 

Net loss

 

Net loss was $8.5 million, or ($0.05) per share for the quarter ended March 31, 2024, compared to a net loss of $10.5 million, or ($0.07) per share for the quarter ended March 31, 2023. The $2 million decrease in the net loss was due to decreases of $1.1 million in research and development expenses and $0.5 million in general and administrative expenses, and the increase in other income of $2.3 million, being partially offset by the increase in stock-based compensation expense of $1.9 million.

 

Net loss was $17.8 million, or ($0.11) per share for the six months ended March 31, 2024, compared to a net loss of $14.1 million, or ($0.10) per share for the six months ended March 31, 2023. The increase in the net loss was primarily due to the increase in stock-based compensation expense.

 

About Citius Pharmaceuticals, Inc.

 

Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company’s diversified pipeline includes two late-stage product candidates. At the end of 2023, Citius completed enrollment in a Phase 3 pivotal superiority trial of Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. The Biologics License Application for LYMPHIR™, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target action date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.

 

3

 

 

Forward-Looking Statements

 

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “plan,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities, including those from existing and new pipeline assets; our need for substantial additional funds; uncertainties relating to preclinical and clinical testing; the FDA may not approve LYMPHIR; our ability to commercialize our products if approved by the FDA; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the early stage of products under development; market and other conditions; our ability to attract, integrate, and retain key personnel; risks related to our growth strategy; our ability to realize some or all of the benefits expected to result from the anticipated spinoff of Citius Oncology or the delay of such benefits; our ongoing businesses which may be adversely affected and subject to certain risks and consequences as a result of the anticipated spinoff transaction; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by Covid-19 and could be impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC’s website at www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2023, filed with the SEC on December 29, 2023, and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

 

Investor Relations for Citius Pharmaceuticals:

 

Investor Contact:

 

Ilanit Allen

ir@citiuspharma.com

908-967-6677 x113

 

Media Contact:

 

STiR-communications

Greg Salsburg

Greg@STiR-communications.com

 

-- Financial Tables Follow –

 

4

 

 

CITIUS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

   March 31,   September 30, 
   2024   2023 
ASSETS        
Current Assets:        
Cash and cash equivalents  $12,559,607   $26,480,928 
Prepaid expenses   9,014,124    7,889,506 
Total Current Assets   21,573,731    34,370,434 
           
Property and equipment, net   275    1,432 
Operating lease right-of-use asset, net   352,505    454,426 
Deposits   38,062    38,062 
In-process research and development   59,400,000    59,400,000 
Goodwill   9,346,796    9,346,796 
           
Total Assets  $90,711,369   $103,611,150 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities:          
Accounts payable  $2,669,507   $2,927,334 
Accrued expenses   151,204    476,300 
Accrued compensation   1,123,076    2,156,983 
Operating lease liability   229,733    218,380 
Total Current Liabilities   4,173,520    5,778,997 
           
Deferred tax liability   6,425,800    6,137,800 
Operating lease liability – noncurrent   145,098    262,865 
Total Liabilities   10,744,418    12,179,662 
           
Commitments and Contingencies          
           
Stockholders’ Equity:          
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding   —    — 
Common stock – $0.001 par value; 400,000,000 shares authorized; 159,094,781 and 158,857,798 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively   159,095    158,858 
Additional paid-in capital   259,214,194    252,903,629 
Accumulated deficit   (180,006,718)   (162,231,379)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity   79,366,571    90,831,108 
Non-controlling interest   600,380    600,380 
Total Equity   79,966,951    91,431,488 
           
Total Liabilities and Equity  $90,711,369   $103,611,150 

 

5

 

 

CITIUS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2024 AND 2023

(Unaudited)

 

   Three Months Ended   Six Months Ended 
   March 31,   March 31,   March 31,   March 31, 
   2024   2023   2024   2023 
Revenues  $—   $—   $—   $— 
                     
Operating Expenses                    
Research and development   3,605,898    4,726,855    6,227,808    8,172,370 
General and administrative   4,285,911    4,792,850    7,946,639    7,396,137 
Stock-based compensation – general and administrative   3,078,392    1,165,595    6,136,577    2,366,676 
Total Operating Expenses   10,970,201    10,685,300    20,311,024    17,935,183 
                     
Operating Loss   (10,970,201)   (10,685,300)   (20,311,024)   (17,935,183)
                     
Other Income                    
Interest income   182,205    303,275    435,843    517,824 
Gain on sale of New Jersey net operating losses   2,387,842    —    2,387,842    3,585,689 
Total Other Income   2,570,047    303,275    2,823,685    4,103,513 
                     
Loss before Income Taxes   (8,400,154)   (10,382,025)   (17,487,339)   (13,831,670)
Income tax expense   144,000    144,000    288,000    288,000 
                     
Net Loss  $(8,544,154)  $(10,526,025)  $(17,775,339)  $(14,119,670)
                     
Net Loss Per Share - Basic and Diluted  $(0.05)  $(0.07)  $(0.11)  $(0.10)
                     
Weighted Average Common Shares Outstanding                    
Basic and diluted   159,072,239    146,251,945    159,013,769    146,231,313 

 

6

 

 

CITIUS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED MARCH 31, 2024 AND 2023

(Unaudited)

 

   2024   2023 
Cash Flows From Operating Activities:        
Net loss  $(17,775,339)  $(14,119,670)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation expense   6,136,577    2,366,676 
Issuance of common stock for services   174,225    102,000 
Amortization of operating lease right-of-use asset   101,921    93,869 
Depreciation   1,157    1,461 
Deferred income tax expense   288,000    288,000 
Changes in operating assets and liabilities:          
Prepaid expenses   (1,124,618)   (2,983,022)
Accounts payable   (257,827)   1,560,215 
Accrued expenses   (325,096)   845,442 
Accrued compensation   (1,033,907)   (736,474)
Operating lease liability   (106,414)   (95,932)
Net Cash Used In Operating Activities   (13,921,321)   (12,677,435)
           
Cash Flows From Financing Activities:          
Proceed from common stock option exercise   —    31,267 
Net Cash Provided By Financing Activities   —    31,267 
           
Net Change in Cash and Cash Equivalents   (13,921,321)   (12,646,168)
Cash and Cash Equivalents - Beginning of Period   26,480,928    41,711,690 
Cash and Cash Equivalents - End of Period  $12,559,607   $29,065,522 

 

 

7

 

 

 EX-101.SCH 3 ctxr-20240514.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ctxr-20240514_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ctxr-20240514_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 14, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 14, 2024
Entity File Number 001-38174
Entity Registrant Name Citius Pharmaceuticals, Inc.
Entity Central Index Key 0001506251
Entity Tax Identification Number 27-3425913
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 11 Commerce Drive
Entity Address, Address Line Two 1st Floor
Entity Address, City or Town Cranford
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07016
City Area Code 908
Local Phone Number 967-6677
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol CTXR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://citiuspharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ctxr-20240514.xsd ctxr-20240514_lab.xml ctxr-20240514_pre.xml ea0206086-8k_citius.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0206086-8k_citius.htm": { "nsprefix": "CTXR", "nsuri": "http://citiuspharma.com/20240514", "dts": { "schema": { "local": [ "ctxr-20240514.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ctxr-20240514_lab.xml" ] }, "presentationLink": { "local": [ "ctxr-20240514_pre.xml" ] }, "inline": { "local": [ "ea0206086-8k_citius.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://citiuspharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0206086-8k_citius.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0206086-8k_citius.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-24-042966-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-042966-xbrl.zip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ea0206086-8k_citius_htm.xml IDEA: XBRL DOCUMENT 0001506251 2024-05-14 2024-05-14 iso4217:USD shares iso4217:USD shares false 0001506251 8-K 2024-05-14 Citius Pharmaceuticals, Inc. NV 001-38174 27-3425913 11 Commerce Drive 1st Floor Cranford NJ 07016 908 967-6677 false false false false Common stock, $0.001 par value CTXR NASDAQ false